Hepatitis B - Pipeline Review, Q1 2011

May 31, 2011

http://www.researchandmarkets.com/reportinfo.asp?report_id=1574058 & t=d & cat_id=

Research and Markets: Hepatitis B - Pipeline Review, Q1 2011

DUBLIN--(BUSINESS WIRE)--Research and Markets

(http://www.researchandmarkets.com/research/173378/hepatitis_b_pipe) has

announced the addition of Global Markets Direct's new report " Hepatitis B -

Pipeline Review, Q1 2011 " to their offering.

Hepatitis B - Pipeline Review, Q1 2011

Global Markets Direct, March 2011, Pages: 102

Summary

Global Markets Direct’s, 'Hepatitis B - Pipeline Review, Q1 2011', provides an

overview of the Hepatitis B Infection therapeutic pipeline. This report provides

information on the therapeutic development for Hepatitis B Infection, complete

with latest updates, and special features on late-stage and discontinued

projects. It also reviews key players involved in the therapeutic development

for Hepatitis B Infection. 'Hepatitis B - Pipeline Review, Q1 2011' is built

using data and information sourced from Global Markets Direct’s proprietary

databases, Company/University websites, SEC filings, investor presentations and

featured press releases from company/university sites and industry-specific

third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the

availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Hepatitis B Infection.

- A review of the Hepatitis B Infection products under development by companies

and universities/research institutes based on information derived from company

and industry-specific sources.

- Coverage of products based on various stages of development ranging from

discovery till registration stages.

- A feature on pipeline projects on the basis of monotherapy and combined

therapeutics.

- Coverage of the Hepatitis B Infection pipeline on the basis of therapeutic

class, route of administration and molecule type.

- Profiles of late-stage pipeline products featuring sections on product

description, mechanism of action and research & development progress.

- Key discontinued pipeline projects.

- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under

development for Hepatitis B Infection.

- Identify emerging players with potentially strong product portfolio and design

effective counter-strategies to gain competitive advantage.

- Plan mergers and acquisitions effectively by identifying players with the most

promising pipeline.

- Devise corrective measures for pipeline projects by understanding Hepatitis B

Infection pipeline depth and focus of Hepatitis B Infection therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying

prospective partners with the most attractive projects to enhance and expand

business potential and scope.

- Modify the therapeutic portfolio by identifying discontinued projects and

understanding the factors that drove them from pipeline.

May 31, 2011